ReviewACS omega2025
Revolutionizing Cancer Care: The Role of 3D Printing in Personalized Oncology.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The promising applications of 3D printing technology for diagnosis and therapy of cancer: Recent advances and challenges.BioImpacts : BI · 2026Review
- Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundrecent advancements in three-dimensional (3D) printing technology have transformed cancer care by enabling the development of highly personalized and efficient therapeutic solutions. This review provides a comprehensive overview of the latest 3D printing methodologies and their integration into oncology, highlighting their diverse applications across various cancer types.
resultskey fabrication techniques, such as fused deposition modeling (FDM), stereolithography (SLA), and semisolid extrusion, are explored, highlighting their ability to produce intricate, patient-specific structures with tailored mechanical and biological properties. These technologies have revolutionized cancer treatment by creating anatomical models that enhance surgical planning, drug delivery systems that enable localized and controlled release, and patient-specific implants that improve clinical outcomes. The application of 3D printing has extended to diverse cancer types, including lungs, colorectal, breast, and ovarian cancers, facilitating the development of tumor microenvironment models for studying cancer progression, drug resistance, and treatment response. Additionally, 3D-printed molds and boluses have demonstrated improved precision in radiation therapy by ensuring accurate delivery tailored to individual patient anatomy. By bridging engineering and medicine, 3D printing offers a transformative approach for addressing the complexities of oncology.
conclusionsthis review highlights the transformative role of 3D printing in modern cancer care, emphasizing its capacity to drive innovation, enable personalized treatment strategies, and enhance precision, ultimately improving therapeutic outcomes and patient care. Furthermore, this review integrates the latest developments regarding the application of 3D printing technology in cancer treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.